Eli Lilly stock broke out of a flat base and reached a record high. Its Mounjaro drug sales surged 91% in the second quarter.

Hims & Hers Health, Inc. (NYSE:HIMS) shares fell over 2% on Tuesday even after the telehealth company posted second-quarter revenue of $753.2 million, up 38% and above the $699 million analysts expected. The firm raised its full-year revenue outlook. Novo Nordisk A/S (NYSE:NVO) suffered a similar fate a week earlier, with shares dropping about 6% […]

NVO's U.S. launch of Awiqli introduces the first once-weekly basal insulin, potentially giving the company a new growth opportunity beyond its pressured GLP-1 franchise.

The battle between Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) has so far been defined by blockbuster injectable weight loss drugs. But the next phase of that rivalry may look very different. Instead of competing over weekly injections, both companies are now racing to establish themselves in what could become the next major opportunity in […]

Novo Nordisk stock has fallen sharply over the past three years, yet the broader valuation checks still flag it as looking cheap rather than stretched. Recent headlines around obesity treatments, intellectual property protection and a large buyback programme add extra context to whether that discount is justified. The share price has declined 49.9% over the past three years, which suggests many investors have already reset their expectations for the stock. Growth expectations around GLP-1...

Lilly, Novo, and Merck have each priced in a radically different version of the next two years, and one of them looks like a setup where the market has it badly wrong.

Eli Lilly's GLP-1 portfolio outpaces its rival in Q2, while Foundayo gains momentum and can challenge Wegovy's early oral obesity lead.

PFE aims to break into the obesity market with berobenatide, a potential monthly treatment designed to compete with leading GLP-1 therapies.

ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.

ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.

Eli Lilly just became the first pharmaceutical company ever valued above $1 trillion, yet analysts who dig into its pipeline are arguing the market still has not grasped what the next two years could look like for shareholders.

The study will run into 2028, testing two low doses of Wegovy, and follows the company disclosing recently that uptake of the pill had been particularly strong for its lowest doses across self-paying patients.

The weight-loss pills battle between Eli Lilly and Novo Nordisk could add to the projected $200 billion market for obesity drugs.

The study’s main goal is to measure the percentage change in participants’ body weight after 60 weeks.

As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.

Eli Lilly is Tuesday's IBD Stock Of The Day. Shares are staring down two potential entries as the weight-loss kingpin gains on Novo Nordisk.

Investing.com -- Hims & Hers Chief Executive Andrew Dudum defended the telehealth company against a Federal Trade Commission lawsuit concerning its data sharing practices in an interview that aired Tuesday on CNBC's "Squawk Box."

Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.

Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.

STORY: From robots taking to the field, to an old-school way to orbit, this is Tech Weekly. :: Tech Weekly Competitors are limbering up for the second World Humanoid Robot Games in Beijing. Bots have been honing their skills in sports including soccer, with the occasional foul along the way. Nearly 30 international teams from 16 countries are set to take part when the games kick off on Saturday. Novo Nordisk boss Mike Doustdar says investors are getting it wrong on the fast-growing obesity drug market. He says patients will increasingly choose between drugs based on factors besides weight loss. “I think five years from now, more and more people would tell you that besides losing weight, I do want to have a reduced risk of a heart attack, a reduced risk of a stroke, a liver that's healthy and not fatty.” The Danish firm dominates the weight-loss drug market, alongside U.S. rival Eli Lilly. OpenAI and Nvidia have struck another big financing deal. The chipmaker will guarantee up to $105 billion to help the chatbot maker lease a massive data center being developed in Ohio. Critics say such deals add to worries over so-called circular financing, where money flows back and forth between the same companies. :: B2Space Satellites could get an old-fashioned ride to space. UK-Spanish startup B2Space is using balloons to lift rockets into the stratosphere, from where it’s cheaper and easier to get to orbit. Co-founder Valentin Canales says the balloons can also carry systems that complement satellites: “So for example sometimes when there are emergencies or disasters the communication infrastructure breaks apart and there’s no mobile phone coverage, there is no radio coverage. So we can put radios on these balloons, fly them very high and they can act as a communications relay to connect people that are very far away.” And France’s top court has blocked a bill banning social media for under-15s, ruling that the move infringed freedom of expression. President Emmanuel Macron has asked his government to rewrite the legislation in response. France is the first country in Europe to follow Australia’s pioneering ban on access to TikTok and other such platforms for young people.

Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising competition remain key risks.

On August 10, Eli Lilly and Company (NYSE:LLY)’s weight-loss pill Foundayo won approval in the UK, becoming the first country in Europe to clear the drug for both weight management and type 2 diabetes. It’s only the second GLP-1 pill approved in Europe, arriving two months after Novo Nordisk A/S (NYSE:NVO)’s Wegovy pill got its […]

This article first appeared on GuruFocus. Novo Nordisk AS (NYSE:NVO) recently announced a total dividend of $0.58 per share, with the ex-dividend date set for 2026-08-17. This payment includes a $0.58 per share cash dividend payable on 2026-08-25.

On August 5, Eli Lilly (NYSE:LLY) told investors its second quarter delivered 48% revenue growth, and the days since have brought even more good news. A UK regulatory approval, a new Medicare access program, and a pipeline addition have all landed in the same short stretch. For a stock that already dominates weight loss, the […]

Novo Nordisk (CPSE:NOVO B) just confirmed an interim cash dividend of DKK 3.75 per share for 2026, with the stock set to trade ex dividend on 14 August, placing shareholder returns in focus. See our latest analysis for Novo Nordisk. Recent earnings, fresh competition in GLP-1 obesity treatments and the confirmed interim dividend have all come against a weaker tape for Novo Nordisk, with the share price down 10.8% over the past month and the 1 year total shareholder return declining 5.3%. This...

Eli Lilly and Company (NYSE:LLY) cleared a notable regulatory hurdle on August 10, when Britain’s drug regulator authorized the company’s oral GLP-1 drug orforglipron, becoming the first country in Europe to approve the pill. Shares of LLY increased more than 2% in response to the announcement, a modest but insightful reaction for a company whose […]

Two healthcare players, Scholar Rock Holding Corporation (NASDAQ:SRRK) and Novo Nordisk A/S (NYSE:NVO), find their near-term narratives intertwined over manufacturing compliance. One is smoothly navigating a supply chain hurdle ahead of a critical drug approval, while the other just delivered a complicated financial quarter. The contrast reveals how investors weigh proactive execution against noisy financial […]

Shares of Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) experienced sharp volatility following its latest quarterly results. On the August 12 episode of Mad Money, Jim Cramer pointed out the disconnect between the company’s strong performance and Wall Street’s initial negative knee-jerk reaction. Cramer commented: Alright, what happened to the stock of Novo Nordisk, the […]

They are way more than just GLP-1 stocks.

Novo argues that differentiated treatments--not a single dominant drug--will determine its position against Eli Lilly.

West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.

WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.

A marketing dispute could reshape a crucial competitive advantage

It's yet another setback for the drugmaker.

The European stock markets closed mixed in Thursday trading as The Stoxx Europe edged 0.1% lower, Ge

European equities traded in the US as American depositary receipts were higher late Thursday morning

Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the country. The approval adds a non injectable option alongside Novo Nordisk's GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk and Eli Lilly medications. These...

NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies threaten to widen the competitive gap.

Lilly's Foundayo records $98M in Q2 sales, while rising prescriptions, broader access and global expansion set the stage for H2 growth

Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right buyer. The question is which pharma giant moves first.

Novo Nordisk's CEO conceded Eli Lilly is gaining market share even as oral Wegovy hits record prescriptions and the stock keeps falling.

Wegovy pill upside has already played out, leaving the multiple at the European pharma average

European equities traded in the US as American depositary receipts were edging lower late Wednesday

NVO faces near-term pressure from flat Wegovy sales, pricing challenges and pipeline setbacks, but its broad cardiometabolic pipeline offers long-term potential.

PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.

With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market even opens.

Novo Nordisk is playing catch-up in the GLP-1 race.

A new market could accelerate Lilly's oral obesity ambitions

European equities traded in the US as American depositary receipts were tracking higher late Tuesday